Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01574716 · ClinicalTrials.gov registry record · Phase 2
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
A Phase 2 study of Metastatic Soft Tissue Sarcoma, sponsored by Morphotek.
- Completed
- Registry status
- Phase 2
- Development phase
- 209
- Enrollment target
- 20
- Study locations
NCT01574716 is a Phase 2 study of Metastatic Soft Tissue Sarcoma that has completed, run by Morphotek. The registered enrollment target is 209 participants, above the 123-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (70% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT01574716, a Phase 2 study of Metastatic Soft Tissue Sarcoma, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 209 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG MORAb-004
Study Locations (20)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
California
- Sarcoma Oncology Center - Santa Monica
- UCLA - Santa Monica
New York
- Mount Sinai Medical Center - New York
- Mayo Clinic - Rochester - Rochester
Illinois
- Northwestern Memorial Hospital - Chicago
Iowa
- Siouxland Hematology-Oncology - Sioux City
Maryland
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan Health System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2012-08-07 |
| Est. Completion | 2016-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01574716
The ClinicalTrials.gov registry entry for NCT01574716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (70% higher). The listed sponsor is Morphotek, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT01574716 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT01574716 about?
NCT01574716 is a clinical study titled "Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation". This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.
What is the current status of trial NCT01574716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 209 participants. The study started on 2012-08-07. Estimated completion is 2016-08-02.
What conditions does trial NCT01574716 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma.
What interventions are being tested in trial NCT01574716?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), MORAb-004 (DRUG).
Who is sponsoring clinical trial NCT01574716?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01574716 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
RECRUITING · Phase 2
-
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.